Effects of β-blockers on glucose and lipid metabolism

References

• Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171
   PubMed Web of Science ®Google Scholar
• Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002;287:1003-10
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146
   PubMed Web of Science ®Google Scholar
• Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care 2004;10:926-32
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   Google Scholar
• Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000;21:1368-75
   PubMed Web of Science ®Google Scholar
• Frishman WH. A historical perspective on the development of beta-adrenergic blockers. J Clin Hypertens 2007;9(4 Suppl. 3):19-27
   PubMedGoogle Scholar
• Egan BM, Basile J, Chilton RJ, et al. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich) 2005;7:409-16
   PubMedGoogle Scholar
• Messerli FH, Grossman E. Beta-blockers in hypertension: is carvedilol different?. Am J Cardiol 2004;93:7B-12B
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM 2006;99:431-36
   PubMed Web of Science ®Google Scholar
• Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007;9:269-77
   PubMed Web of Science ®Google Scholar
• Garcia-Puig J, Ruilope LM, Luque M, et al. Glucose metabolism in patients with essential hypertension. Am J Med 2006;119:318-26
   PubMed Web of Science ®Google Scholar
• Izzo Jr JL, Sica DA, Black HR. Hypertension Primer: The Essentials of High Blood Pressure, 4th Edn. Philadelphia: Lippincott Williams & Wilkins, 2008
   Google Scholar
• Halperin RO, Sesso HD, Ma J, et al. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006;47:45-50
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44
   PubMed Web of Science ®Google Scholar
• Govindarajan G, Whaley-Connell A, Mugo M, et al. The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci 2005;330:311-18
   PubMed Web of Science ®Google Scholar
• Pauletto P, Scannapieco G, Pessina AC. Sympathetic drive and vascular damage in hypertension and atherosclerosis. Hypertension 1991;17(4 Suppl.):III75-81
   Web of Science ®Google Scholar
• Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82(12A):67U-73U; discussion 85U-6U
   Web of Science ®Google Scholar
• Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. Faseb J 2001;15:2073-84
   PubMed Web of Science ®Google Scholar
• Sun N, Wood NB, Hughes AD, et al. Effects of transmural pressure and wall shear stress on LDL accumulation in the arterial wall: a numerical study using a multilayered model. Am J Physiol Heart Circ Physiol 2007;292:H3148-57
   PubMed Web of Science ®Google Scholar
• Finet G, Ohayon J, Rioufol G, et al. Morphological and biomechanical aspects of vulnerable coronary plaque. Arch Mal Coeur Vaiss 2007;100:547-53
   PubMedGoogle Scholar
• Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc (2003) 2004;44(2 Suppl. 1):S5-12; quiz S12-13
   Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   Google Scholar
• Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes – 2007. Diabetes Care 2007;30(Suppl. 1):S4-41
   PubMedGoogle Scholar
• Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
   PubMed Web of Science ®Google Scholar
• Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 2008;156:112-19
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999;34(4 Pt 2):724-8
   PubMed Web of Science ®Google Scholar
• Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998;41(1 Suppl. 1):39-52
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-62
   PubMed Web of Science ®Google Scholar
• Bell DS. Optimizing treatment of diabetes and cardiovascular disease with combined alpha,beta-blockade. Curr Med Res Opin 2005;21:1191-200
   PubMed Web of Science ®Google Scholar
• Bangalore S, Messerli FH, Kostis JB, et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007;50:563-72
   PubMed Web of Science ®Google Scholar
• Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489-94
   PubMed Web of Science ®Google Scholar
• Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-9
   PubMed Web of Science ®Google Scholar
• Aberg H, Morlin C, Lithell H. Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension. EGTA Group. J Hum Hypertens 1995;9:149-53
   PubMed Web of Science ®Google Scholar
• Helgeland A, Strommen R, Hagelund CH, et al. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Lancet 1986;1:872-5
   PubMed Web of Science ®Google Scholar
• Jacob S, Klimm HJ, Rett K, et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004;112:315-22
   PubMed Web of Science ®Google Scholar
• Berglund G, Andersson O, Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide. Acta Med Scand 1986;220:419-24
   PubMed Web of Science ®Google Scholar
• Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Hypertension 1985;7(6 Pt 1):1008-16
   Google Scholar
• Sourgens H, Schmidt J, Derendorf H. Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study. Int J Clin Pharmacol Ther 2003;41:22-9
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chappel C, Farnham DJ, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 1992;32:61-5
   PubMed Web of Science ®Google Scholar
• Ruilope LM. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. Am J Hypertens 1994;7:129-36
   PubMed Web of Science ®Google Scholar
• Bagatin J, Sardelic S, Pivac N, et al. Comparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertension. Int J Clin Pharmacol Res 1998;18:73-8
   PubMedGoogle Scholar
• Perez-Stable EJ, Coates TJ, Baron RB, et al. Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension. J Gen Intern Med 1995;10:419-28
   PubMed Web of Science ®Google Scholar
• Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994;43:455-61
   PubMed Web of Science ®Google Scholar
• Khaw K-T, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004;141:413-20
   PubMed Web of Science ®Google Scholar
• Myint PK, Sinha S, Wareham NJ, et al. Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: a threshold relationship?. Stroke 2007;38:271-5
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
   PubMed Web of Science ®Google Scholar
• Gupta AK, Dahlof B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-8
   PubMed Web of Science ®Google Scholar
• Owada A, Suda S, Hata T, et al. The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens 2001;23:305-16
   PubMed Web of Science ®Google Scholar
• Abdelmawla AH, Langley RW, Szabadi E, et al. Bisoprolol attenuates noradrenaline- and phenylephrine-evoked venoconstriction in man in vivo. Br J Clin Pharmacol 1997;44:61-8
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Joglekar SJ, Jaguste V, Nanivadekar AS. Prazosin GITS vs atenolol in patients with hypertension and normal lipid profile: a randomized, controlled multicenter study. Hyderabad Hypertension Study Group. J Assoc Physicians India 1998;Suppl. 1:41-51
   PubMedGoogle Scholar
• Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999;159:551-8
   PubMed Web of Science ®Google Scholar
• Thulin T, Lehtonen A, Dahlof C, et al. Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish–Finnish Study Group. Int J Clin Pharmacol Ther 1999;37:28-33
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Malamani GD, et al. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 1995;39:471-6
   PubMed Web of Science ®Google Scholar
• van der Does R, Widmann L, Uberbacher HJ, et al. Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide. Eur J Clin Pharmacol 1990;38(Suppl. 2):S147-52
   PubMed Web of Science ®Google Scholar
• Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press 1998;7:39-45
   PubMedGoogle Scholar
• Schmitz G, Stumpe KO, Herrmann W, et al. Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial. Blood Press 1996;5:354-9
   PubMedGoogle Scholar
• Rabkin SW, Huff MW, Newman C, et al. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension 1994;24:241-8
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Eff J, Ferraro L, et al. Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects. Am J Cardiol 1993;72:1131-6
   PubMed Web of Science ®Google Scholar
• Otterstad JE, Froeland G, Soeyland AK, et al. Lipid profile in 100 men with moderate hypertension treated for 1 year with atenolol or hydrochlorothiazide plus amiloride: a double-blind, randomized study. Scand J Clin Lab Invest 1992;52:83-93
   PubMed Web of Science ®Google Scholar
• Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up. Am Heart J 1991;121(1 Pt 2):280-5
   PubMed Web of Science ®Google Scholar
• Talseth T, Westlie L, Daae L. A long-term study of atenolol and doxazosin in mild and moderate hypertension. J Hum Hypertens 1990;4(Suppl. 3):39-44
   PubMedGoogle Scholar
• Frick MH, Halttunen P, Himanen P, et al. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986;21(Suppl. 1):55S-62S
   PubMedGoogle Scholar
• Johnston GD, Vyssoulis G, Feely J, et al. Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives: a randomised double-blind long-term parallel group trial. J Hum Hypertens 1995;9:123-9
   PubMed Web of Science ®Google Scholar
• Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl 1995;3:38-46
   PubMedGoogle Scholar
• Foss OP, Jensen EK. The effect of captopril and metoprolol as monotherapy or combined with bendroflumethiazide on blood lipids. J Intern Med 1990;227:119-23
   PubMed Web of Science ®Google Scholar
• Hedner T, Thulin T, Gustafsson S, et al. A comparison of diltiazem and metoprolol in hypertension. Swedish Diltiazem–Metoprolol Multicentre Study Group. Eur J Clin Pharmacol 1990;39:427-33
   PubMed Web of Science ®Google Scholar
• Materson BJ, Vlachakis ND, Glasser SP, et al. Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol. Am J Cardiol 1989;63:58I-63I
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Nissinen A, Honkavaara M. Clinical evaluation of the antihypertensive effect of metoprolol in combination with hydrochlorothiazide and hydralazine in an unselected hypertensive population. Acta Cardiol 1980;35:289-301
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Pasotti C, et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers. J Cardiovasc Pharmacol 1989;14(Suppl. 7):S28-32
   PubMedGoogle Scholar
• Zusman R, Christensen D, Federman E, et al. Comparison of nifedipine and propranolol used in combination with diuretics for the treatment of hypertension. Am J Med 1987;82(3B):37-41
   PubMed Web of Science ®Google Scholar
• Saunders E, Curry C, Hinds J, et al. Labetalol compared with propranolol in the treatment of black hypertensive patients. J Clin Hypertens 1987;3:294-302
   PubMed Web of Science ®Google Scholar
• Goto Y. Effects of alpha- and beta-blocker antihypertensive therapy on blood lipids: a multicenter trial. Am J Med 1984;76(2A):72-8
   PubMed Web of Science ®Google Scholar
• Helgeland A. Double-blind comparison of trimazosin and propranolol in essential hypertension. Am Heart J 1983;106(5 Pt 2):1253-8
   PubMed Web of Science ®Google Scholar
• Tang WH. A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus. Vasc Health Risk Manag 2007;3:639-45
   PubMedGoogle Scholar
• DeFronzo RA, Mandarino L, Ferrannini E. Metabolic and molecular pathogenesis of type 2 diabetes mellitus. In: DeFronzo RA, Ferrannini E, Keen H, Zimmet P (eds). International Textbook of Diabetes Mellitus, 3rd edn. Chichester, UK: John Wiley & Sons Ltd, 2004:359-73
   Google Scholar
• Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Br Med J 1998;317:713-20
   PubMed Web of Science ®Google Scholar
• Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990;300:902-3
   PubMed Web of Science ®Google Scholar
• Afonso RA, Patarrao RS, Macedo MP, et al. Carvedilol’s actions are largely mediated by endogenous nitric oxide. Rev Port Cardiol 2006;25:911-17
   PubMedGoogle Scholar
• COREG CR® (carvedilol phosphate) Extended-release Capsules (prescribing information). Research Triangle Park, NC: GlaxoSmithKline, Inc., 2008
   Google Scholar
• COREG® (carvedilol) Tablets (prescribing information). Research Triangle Park, NC: GlaxoSmithKline, Inc., 2008
   Google Scholar
• Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-107
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36
   PubMed Web of Science ®Google Scholar
• Hauf-Zachariou U, Widmann L, Zulsdorf B, et al. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993;45:95-100
   PubMed Web of Science ®Google Scholar
• Kusljugic Z, Divkovic K, Barakovic F, et al. Effects of nebivolol on artery hypertension – multicentre study Bosnia and Herzegovina. Bosn J Basic Med Sci 2005;5:42-51
   PubMedGoogle Scholar
• Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003;8:127-34
   PubMedGoogle Scholar
• Schmidt AC, Graf C, Brixius K, et al. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig 2007;27:841-9
   PubMed Web of Science ®Google Scholar
• Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006;24:591-6
   PubMed Web of Science ®Google Scholar
• BYSTOLIC® (nebivolol) Tablets (prescribing information). St. Louis, MO: Forest Pharmaceuticals, Inc., 2008
   Google Scholar
• Louis WJ, McNeil JJ, Drummer OH. Pharmacology of combined alpha-beta-blockade. I. Drugs 1984(Suppl. 2):16-34
   Google Scholar
• Ohman KP, Weiner L, von Schenck H, et al. Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. Eur J Clin Pharmacol 1985;29:149-54
   PubMed Web of Science ®Google Scholar
• Siwach SB, Dahiya SS, Seth S, et al. Effect of atenolol and labetalol on serum lipids. J Assoc Physicians India 1993;41:293-4
   PubMedGoogle Scholar
• Frishman WH, Michelson EL, Johnson BF, et al. Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension. Am J Med 1983;75(4A):54-67
   PubMed Web of Science ®Google Scholar
• Schamaun O, Westheim A, Qvigstad EK, et al. A comparative study on the effect of atenolol and labetalol on exercise capacity and lipid serum levels in essential hypertension. Nephron 1987;47(Suppl. 1):135-7
   PubMedGoogle Scholar
• Farry JP, Fischl SJ, Tighe MJ, et al. Effects of prazosin and labetalol on blood pressure control and blood lipid levels in patients with mild-to-moderate essential hypertension. Am J Med 1989;86(1B):41-4
   PubMed Web of Science ®Google Scholar
• Lucas C, Jenkins P, Mendels J, et al. The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients. J Natl Med Assoc 1991;83:866-71
   PubMed Web of Science ®Google Scholar
• Kozlovski VI, Lomnicka M, Chlopicki S. Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol Rep 2006;58(Suppl.):103-10
   PubMedGoogle Scholar
• Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003;100:215-34
   PubMed Web of Science ®Google Scholar
• Giugliano D, Marfella R, Acampora R, et al. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998;21:631-6
   PubMed Web of Science ®Google Scholar
• Gonzalez Maqueda I. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis 1994;5:909-18
   PubMed Web of Science ®Google Scholar
• Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001;104:511-14
   PubMed Web of Science ®Google Scholar
• Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007;25:731-41
   PubMed Web of Science ®Google Scholar
• Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-6
   PubMed Web of Science ®Google Scholar
• Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955-9
   PubMed Web of Science ®Google Scholar
• Maggi E, Marchesi E, Covini D, et al. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996;27:532-8
   PubMed Web of Science ®Google Scholar
• Moreno AJ, Santos DJ, Palmeira CM. Ischemic heart disease: the role of mitochondria – carvedilol prevents lipid peroxidation of mitochondrial membranes. Rev Port Cardiol 1998;17(Suppl. 2):II63-77
   PubMedGoogle Scholar
• Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002;105(24):2867-71
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA 2008;300:2123-33
   PubMed Web of Science ®Google Scholar
• Fratta Pasini A, Garbin U, Nava MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005;23:589-96
   PubMed Web of Science ®Google Scholar
• Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007;25:785-91
   PubMed Web of Science ®Google Scholar
• de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007;16:14-21
   PubMed Web of Science ®Google Scholar
• King DE, Egan BM, Mainous AG 3rd, et al. The effect of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension. J Clin Hypertens (Greenwich) 2006;8:257-60
   PubMedGoogle Scholar
• Messerli FH, Bell DSH, Fonseca V, et al. Body weight changes with beta-blocker use: results from GEMINI. Am J Med 2007;120:610-15
   PubMed Web of Science ®Google Scholar
• Peter P, Martin U, Sharma A, et al. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther 2006;31:153-9
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
   PubMed Web of Science ®Google Scholar
• Torre JJ, Bloomgarden ZT, Dickey RA, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract 2006;12:193-222
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. NICE Clinical Guideline 34. June 2006. Available at: www.nice.org.uk/guidance/index.jsp?action=download&o=30114 [Last accessed 13 January 2009]
   Google Scholar